Merrimack Pharm (MACK) Posts Mixed Q1 Results

Merrimack Pharm (NASDAQ: MACK) reported Q1 EPS of ($0.27), $0.03 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $13.03 million versus the consensus estimate of $11.93 million.

For earnings history and earnings-related data on Merrimack Pharm (MACK) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30